HIGHLIGHTS
- who: Vipul Jairath from the USA USA USA USA have published the research work: Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis, in the Journal: (JOURNAL)
- what: This study provides valuable insights into which advanced therapies for UC provide the highest efficacy relative to their cost to treat, while also incorporating economic consequences from AEs.
SUMMARY
Inflammatory bowel disease (IBD), ulcerative colitis (UC), and Crohn`s disease have a prevalence of approximately 0.5% in the United_States (US). Safety profiles between advanced therapies . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.